non-mA patients: Rosi versus Nat, mA patients: Rosi versus plb
12 weeks
non-mA patients: +18%b, mA patients:
−66%a,b,
NA
ificant changes from
baseline levels or other groups; bchange versus the group compared; cmean change for systolic BP versus baseline in
patients treated with the TZD. DM, diabetes mellitus; hyp,
hypertension; mA, microalbuminuria; MA, macroalbuminuria; Glip, glipizide; Nat,
nateglinide; plb, placebo; Pio, pioglitazone; Vog, voglibose; UAE, urine
albumin excretion; NA, changes in blood pressure levels not applicable.